Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for muscle disorders. Its lead product candidate is sevasemten, an orally administered small molecule currently in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for hypertrophic cardiomyopathy and severe cardiac disorders, currently in Phase I trials, and EDG-15400, a novel small molecule for heart failure with preserved ejection fraction. Additionally, Edgewise has a pipeline of precision medicine candidates targeting key muscle proteins and modulators for genetically defined muscle disorders.

Edgewise Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol EWTX. The company's financials are reported in US Dollars (USD), reflecting its primary operations in the United States. As a US-based company trading on a major US exchange, its stock is traded in USD, and investors typically use US dollars for transactions.

Edgewise Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. This means the company is involved in using biological processes and living organisms to develop therapies for medical conditions. As a biotechnology firm, Edgewise focuses on research and development of novel drugs, particularly for muscle disorders, and its work involves advanced scientific techniques to create targeted treatments.

Edgewise Therapeutics is headquartered in Boulder, Colorado, United States. The company primarily serves the US market, as indicated by its country and region classification. While its therapies are being developed for global muscle disorder patients, its operations, clinical trials, and regulatory focus are centered in the United States. The company was incorporated in 2017 and has since been advancing its pipeline of muscle disorder treatments.

Edgewise Therapeutics' pipeline includes several key product candidates. Sevasemten is the lead candidate, an oral small molecule in Phase II trials for dystrophinopathies like Duchenne and Becker muscular dystrophy. EDG-7500 targets hypertrophic cardiomyopathy and severe cardiac disorders and is in Phase I trials. EDG-15400 is a novel small molecule for heart failure with preserved ejection fraction, also in early development. Additionally, the company has a pipeline of precision medicine candidates that target specific muscle proteins and modulators for genetically defined muscle disorders, aiming to provide tailored therapies for patients.